Telah dil p kukan uji teratogenisitas kiorpropamidapada mencit strain Biomedis, bertujuan untuk lebih dapatmeramalkan apakab kiorpropamida menyebabkan cacat bawaanpada manusia atau tidak. Dosis kiorpropamida yang diguriakanadalah 50 mg/kg BB, 200 mg/kg BB dan 400 mg/kg BB (lebihkurang setara dengan 5X, 20X dan 40X dosis lazim tertinggipada manusia), diberikan per oral melalul sondelambung. Dalam penelitian ml digunakan dua kelompok kon-.trol. Kelompok kontrol I tidak diberikan apa-apa kecualimakarian dan minuman ad libitum seperti halnya kelompok lainnya,sedangkan kelompok kontro]. II diberikan suspensiCNO (vehikel) 0,5%. Pemberian obat kepada kelompok keloladan suspensiCj kepada .kelompok' kontrol II dilakukan selama10 hari yaltu dari hari ke 6 sampal dengan 15 keharnilan.(selarna periode organogenesis). J1encit dimatikan pada harike 18 kehamilan dengan eter dan dilakukan histerektomi.- Pemeniksaan yang dilakukan : juml.ah fetus hidup dengan Cacatbawaan (eksternal dan internal termasuk cacat tulangrangka) yang dapat dilihat secara makroskopis dan jenisCacat bawaan yang terjadi, jumlah fetus hidup tanpa cacat,jumlah resorpsi dri fetus mati intrauterus. Juga dianalisakenaikari berat bp d.an mencit seisma kehamilan.Klorpropamlda dosis 50 mg/kg BB per hari tidk menunjukkanefek yang bermakna balk terhadap terjadinya Cacatbawaan (Fisher test), terhadap frekuensi resorpsi danfetus mati intrauterus (Chi-square test), maupun terhadapkenaikan berat badan induk mencit selama kehamilan (Testanalisa vanians satu arah dan student 't' test).Kiorpropamida dosis 200 mg/kg BB per . hari menunjukkanefek yang bermakna terhadap terjadinya cacat bawaan(Fisher test), tetapi tidak menunjukkan efek yang bermaknaterhada.p frekuensi resorpsl dam kematlan fetus intrauterus(Chi-square test) dan terhadap kenaikan berat badan indukmencit sela.ma kehmllan (Test analisa vanians satu arahdan student I t' test).Kiorpropamida dosis. 400 mg/kg BB per hari menunjukkanefek yang bermakna terhadap terjadlnya cacat bawaan(Fisher test), terhadap frekuensi resorpsi dan kematianfetus intrauterus (chi-square test) dan terhadap kenaikanberat badan induk mencit selama keharnhla.n (Test analisavanians satu srah dan student 't' test).Jenis cacat bawsan yang merupakan efek yang bermaknads.ri kiorpropamida adiah 'cleft palate' (Fisher test).

---

The teratogenicity of chiorproparnide has been investigted

on Biomedis strain mice, in order to be able

to predict whether chiorpropamide causes congenital mall ormations

in man or not. The dosages of 50 mg/kg B.W., 200 mg/

kg B.W. and 400 mg/kg B.W. (equivalent to about 5, 20 9 and

40 times the higest usual dose in man) daily were used,,

They were given orally with a stomach tube. This investigation

had two control groups. The first one was given nothing

except diet given ad libitum and the second one was given

suspension of 0,5 % CMC. ChJorpropnmlde suspensions ind CMC

suspension were respectively given to treated groups of mice

and the second control group for 10 days i.e. on 6 to 15th

of gestation day (orgsnogenesis period). The animals were

sacrificed on 18th day of pregnancy by an over dose of ether.

The number of all living and intact, dead and resorbed, and

malformed fetuses (evaluated macroscopically), the kind of

malformations (external and internal malformations, including

skeletal defects) were observed and recorded. The weight

gain along the pregnancy were also analysed.

With dnily doses of 50 mg/kg B.W. , chlorpropimide

didn't show significant effects on the congenital anomalies

prevalence (Fisher test), the frequency of resorptions and

intrauterine deaths (Chi-square test) and the weight gain

along the pregnancy (Analysis of variance one way test and

Student 't' test).

With daily doses of 200 mg/kg B.W., chiorpropamide

showed significant effect on the congenital anomalies prevalence

(Fisher test), but it didn't show significant effect

on the frequency of resorptions and Intrauterine deaths

(Chi-square test) and the weight gain along the pregnancy

(Analysis of variance one way test and Student 't' test).

With daily doses of 400 mg/kg B.W., chiorpropamide

showed significant effects on the congenital anomalies prevalence

(Fisher test), the frequency of resorptions and intrauterine

deaths (Chi-square test) and the weight gain

along the pregnancy (Analysis of variance one way test and

Student I t' test).

The kind of congenital anomaly which was significant

effect of chiorpropamide was cleft palate (Fisher test).